ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCAB Subcommittee Tells Califano To Keep Hands Off Board Appointments

May 18, 1979

Sept. Is AMA’s Month of Women In Medicine

September 10, 1993

CDC Study Finds No Correlation Between Alcohol, Breast Cancer

April 8, 1988

In Brief: Henney To Leave NCI For Kansas; Dan Longo Heads BRMP; DeVita To Receive Nervi Award

May 10, 1985

NCI To Merge Two Intramural Divisions To Form Center For Cancer Research.

January 12, 2001

In Brief: Centers Survey Generates Only 56 Responses GAO to Report On NCI’s Dissemination Efforts

January 22, 1988